Wonder

Dapoxetine.

Each film coated tablet contains Dapoxetine hydrochloride equivalent to Dapoxetine 30 mg/60 mg.
Excipients/Inactive Ingredients: Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl methylcellulose, magnesium stearate, opadry grey 03K575000 and purified water.

Pharmacotherapeutic group: Other Urologicals. ATC code: G04BX14.
Pharmacology: Pharmacodynamics: Wonder contains Dapoxetine which is a potent selective serotonin reuptake inhibitor (SSRI) with an IC₅₀ of 1.12 nM, while its major human metabolites, desmethyldapoxetine (IC₅₀ < 1.0 nM) and didesmethyldapoxetine (IC₅₀ = 2.0 nM) are equivalent or less potent (Dapoxetine-N-oxide (IC₅₀ = 282 nM)).
Human ejaculation is primarily mediated by the sympathetic nervous system. The ejaculatory pathway originates from a spinal reflex centre, mediated by the brain stem, which is influenced initially by a number of nuclei in the brain (medial preoptic and paraventricular nuclei).
The mechanism of action of Dapoxetine in premature ejaculation is presumed to be linked to the inhibition of neuronal reuptake of serotonin and the subsequent potentiation of the neurotransmitter's action at pre and postsynaptic receptors.
Pharmacokinetics: Absorption: Dapoxetine is rapidly absorbed with maximum plasma concentrations (C_max) occurring approximately 1-2 hours after tablet intake. The absolute bioavailability is 42% (range 15-76%), and dose proportional increases in exposure (AUC and C_max) are observed between the 30 and 60 mg dose strengths. Following multiple doses, AUC values for both Dapoxetine and the active metabolite desmethyldapoxetine (DED) increase by approximately 50% when compared to single dose AUC values.
Ingestion of a high fat meal modestly reduced the C_max (by 10%) and modestly increased the AUC (by 12%) of Dapoxetine and slightly delayed the time for Dapoxetine to reach peak concentrations. These changes are not clinically significant. Dapoxetine can be taken with or without food.
Distribution: More than 99% of dapoxetine is bound in vitro to human serum proteins. The active metabolite desmethyldapoxetine (DED) is 98.5% protein bound. Dapoxetine has a mean steady state volume of distribution of 162 L.
Metabolism: In vitro studies suggest that dapoxetine is cleared by multiple enzyme systems in the liver and kidneys, primarily CYP2D6, CYP3A4, and flavin monooxygenase (FMO1). Following oral dosing of ¹⁴C-Dapoxetine, Dapoxetine was extensively metabolized to multiple metabolites primarily through the following biotransformational pathways: N-oxidation, N-demethylation, naphthyl hydroxylation, glucuronidation and sulfation. There was evidence of presystemic first-pass metabolism after oral administration.
Intact Dapoxetine and Dapoxetine-N-oxide were the major circulating moieties in the plasma. In vitro binding and transporter studies show that Dapoxetine-N-oxide is inactive. Additional metabolites including desmethyldapoxetine and didesmethyldapoxetine account for less than 3% of the total circulating drug-related materials in plasma. In vitro binding studies indicate that DED is equipotent to Dapoxetine and didesmethyldapoxetine has approximately 50% of the potency of Dapoxetine. The unbound exposures (AUC and C_max) of DED are approximately 50% and 23%, respectively, of the unbound exposure of Dapoxetine.
Elimination: The metabolites of Dapoxetine were primarily eliminated in the urine as conjugates. Unchanged active substance was not detected in the urine. Following oral administration, Dapoxetine has an initial (disposition) half-life of approximately 1.5 hours, with plasma levels less than 5% of peak concentrations by 24 hours post-dose, and a terminal half-life of approximately 19 hours. The terminal half-life of DED is approximately 19 hours.
Pharmacokinetics in special populations: The metabolite DED contributes to the pharmacological effect of Wonder, particularly when the exposure of DED is increased. As follows, in some populations, the increase in active fraction parameters is presented. This is the sum of the unbound exposure of dapoxetine and DED. DED is equipotent to dapoxetine. The estimation assumes equal distribution of DED to the CNS but it is unknown whether this is the case.
Race: Analyses of single dose clinical pharmacology studies using 60 mg dapoxetine indicated no statistically significant differences between Caucasians, Blacks, Hispanics and Asians. A clinical study conducted to compare the pharmacokinetics of dapoxetine in Japanese and Caucasian subjects showed 10% to 20% higher plasma levels (AUC and peak concentration) of dapoxetine in Japanese subjects due to lower body weight. The slightly higher exposure is not expected to have a meaningful clinical effect.
Elderly (age 65 years and over): Analyses of a single dose clinical pharmacology study using 60 mg dapoxetine showed no significant differences in pharmacokinetic parameters (C_max, AUC_inf, T_max) between healthy elderly males and healthy young adult males. The efficacy and safety has not been established in this population (see Dosage & Administration).
Renal impairment: A single-dose clinical pharmacology study using a 60 mg dapoxetine dose was conducted in subjects with mild (CrCL 50 to 80 mL/min), moderate (CrCL 30 to < 50 mL/min), and severe renal impairment (CrCL < 30 mL/min) and in subjects with normal renal function (CrCL > 80 mL/min). No clear trend for an increase in dapoxetine AUC with decreasing renal function was observed. AUC in subjects with severe renal impairment was approximately 2-fold that of subjects with normal renal function, although there are limited data in patients with severe renal impairment. Dapoxetine pharmacokinetics have not been evaluated in patients requiring renal dialysis (see Dosage & Administration and Precautions).
Hepatic impairment: In patients with mild hepatic impairment, unbound C_max of dapoxetine is decreased by 28% and unbound AUC is unchanged. The unbound C_max and AUC of the active fraction (the sum of the unbound exposure of dapoxetine and desmethyldapoxetine) were decreased by 30% and 5%, respectively. In patients with moderate hepatic impairment, unbound C_max of dapoxetine is essentially unchanged (decrease of 3%) and unbound AUC is increased by 66%. The unbound C_max and AUC of the active fraction were essentially unchanged and doubled, respectively.
In patients with severe hepatic impairment, the unbound C_max of dapoxetine was decreased by 42% but the unbound AUC was increased by approximately 223%. The C_max and AUC of the active fraction had similar changes (see Dosage & Administration and Contraindications).
CYP2D6 Polymorphism: In a single dose clinical pharmacology study using 60 mg dapoxetine, plasma concentrations in poor metabolizers of CYP2D6 were higher than in extensive metabolizers of CYP2D6 (approximately 31% higher for C_max and 36% higher for AUC_inf of dapoxetine and 98% higher for C_max and 161% higher for AUC_inf of desmethyldapoxetine). The active fraction of Wonder may be increased by approximately 46% at C_max and by approximately 90% at AUC. This increase may result in a higher incidence and severity of dose dependent adverse events (see Dosage & Administration). The safety of Wonder in poor metabolizers of CYP2D6 is of particular concern with concomitant administration of other medicinal products that may inhibit the metabolism of dapoxetine such as moderate and potent CYP3A4 inhibitors (see Dosage & Administration and Contraindications).

Wonder tablets are indicated for the treatment of premature ejaculation (PE) in adult men aged 18 to 64 years.
Wonder tablets should only be prescribed to patients who meet all the following criteria: An intravaginal ejaculatory latency time (IELT) of less than two minutes; and Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and Marked personal distress or interpersonal difficulty as a consequence of PE; and Poor control over ejaculation; and A history of premature ejaculation in the majority of intercourse attempts over the prior 6 months.
Wonder tablets should be administered only as on-demand treatment before anticipated sexual activity. It should not be prescribed to delay ejaculation in men who have not been diagnosed with PE.

Dosage: Adult men (aged 18 to 64 years): The recommended starting dose for all patients is 30 mg, taken as needed approximately 1 to 3 hours prior to sexual activity. Treatment with Wonder should not be initiated with the 60 mg dose.
Wonder tablet is not intended for continuous daily use. It should be taken only when sexual activity is anticipated and must not be taken more frequently than once every 24 hours.
If the individual response to 30 mg is insufficient and the patient has not experienced moderate or severe adverse reactions or prodromal symptoms suggestive of syncope, the dose may be increased to a maximum recommended dose of 60 mg taken as needed approximately 1 to 3 hours prior to sexual activity. The incidence and severity of adverse events is higher with the 60 mg dose.
If the patient experienced orthostatic reactions on the starting dose, no dose escalation to 60 mg should be performed.
A careful appraisal of individual benefit risk of Wonder should be performed by the physician after the first four weeks of treatment (or at least after 6 doses of treatment) to determine whether continuing treatment with Wonder is appropriate.
Data regarding the efficacy and safety of Wonder beyond 24 weeks are limited. The clinical need of continuing and the benefit risk balance of treatment with Wonder should be re-evaluated at least every six months.
Elderly (age 65 years and over): The efficacy and safety of Wonder tablets have not been established in patient's age 65 years and over.
Paediatric population: There is no relevant use of Wonder tablets in this population in the indication of premature ejaculation.
Patients with renal impairment: Caution is advised in patients with mild or moderate renal impairment. Wonder tablet is not recommended for use in patients with severe renal impairment.
Patients with hepatic impairment: Wonder tablet is contraindicated in patients with moderate and severe hepatic impairment (Child-Pugh Class B and C) .
Known CYP2D6 poor metabolizers or patients treated with potent CYP2D6 inhibitors: Caution is advised if increasing the dose to 60 mg in patients known to be of CYP2D6 poor metabolizer genotype or in patients concomitantly treated with potent CYP2D6 inhibitors.
Patients treated with moderate or potent inhibitors of CYP3A4: Concomitant use of potent CYP3A4 inhibitors is contraindicated. The dose should be restricted to 30 mg in patients concomitantly treated with moderate CYP3A4 inhibitors and caution is advised.
Method of administration: For oral use.
Wonder tablet should be swallowed whole to avoid the bitter taste. It is recommended that tablets be taken with at least one full glass of water and may be taken with or without food.
Precautions to be taken before handling or administering the medicinal product: Before treatment is initiated, see "Precautions" regarding orthostatic hypotension.

No case of overdose has been reported.
There were no unexpected adverse events in a clinical pharmacology study of Wonder with daily doses up to 240 mg (two 120 mg doses given 3 hours apart). In general, symptoms of overdose with SSRIs include serotonin mediated adverse reactions such as somnolence, gastrointestinal disturbances such as nausea and vomiting, tachycardia, tremor, agitation and dizziness.
In cases of overdose, standard supportive measures should be adopted as required. Due to high protein binding and large volume of distribution of dapoxetine hydrochloride, forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for Wonder are known.

Hypersensitivity to the active substance or to any of the excipients listed previously.
Significant pathological cardiac conditions such as: Heart failure (NYHA class II-IV); Conduction abnormalities such as AV block or sick sinus syndrome; Significant ischemic heart disease; Significant valvular disease; A history of syncope.
A history of mania or severe depression.
Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing treatment with an MAOI. Similarly, an MAOI should not be administered within 7 days after Wonder has been discontinued.
Concomitant treatment with thioridazine, or within 14 days of discontinuing treatment with thioridazine. Similarly, thioridazine should not be administered within 7 days after Wonder has been discontinued.
Concomitant treatment with serotonin reuptake inhibitors [selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs)] or other medicinal/herbal products with serotonergic effects [e.g., L-tryptophan, triptans, tramadol, linezolid, lithium, St. John's Wort (Hypericum perforatum)] or within 14 days of discontinuing treatment with these medicinal/herbal products. Similarly, these medicinal/herbal products should not be administered within 7 days after Wonder has been discontinued.
Concomitant treatment of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazadone, nelfinavir, atazanavir, etc.
Moderate and severe hepatic impairment.

General recommendations: Dapoxetine tablet is only indicated in men with Premature Ejaculation who meet all the criteria listed in sections of therapeutic indications and pharmacodynamics. Dapoxetine tablet should not be prescribed to men who have not been diagnosed with Premature Ejaculation. Safety has not been established and there are no data on the ejaculation-delaying effects in men without Premature Ejaculation.
Other forms of sexual dysfunction: Before treatment, subjects with other forms of sexual dysfunction, including erectile dysfunction, should be carefully investigated by physicians. Dapoxetine tablet should not be used in men with erectile dysfunction (ED) who are using PDE5 inhibitors.
Orthostatic hypotension: Before treatment initiation, a careful medical examination including history of orthostatic events should be performed by the physician. An orthostatic test should be performed before initiating therapy (blood pressure and pulse rate, supine and standing). In case of a history of documented or suspected orthostatic reaction, treatment with dapoxetine should be avoided.
Orthostatic hypotension has been reported in clinical trials. The prescriber should counsel the patient in advance that if he experiences possibly prodromal symptoms, such as lightheadedness soon after standing, he should immediately lie down so his head is lower than the rest of his body or sit down with his head between his knees until the symptoms pass. The prescriber should also inform the patient not to rise quickly after prolonged lying or sitting.
Suicide/suicidal thoughts: Antidepressants, including SSRIs, increased the risk compared to placebo of suicidal thinking and suicidality in short-term studies in children and adolescents with Major Depressive Disorder and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24. In clinical trials with Wonder for the treatment of premature ejaculation, there was no clear indication of treatment-emergent suicidality in evaluation of possibly suicide-related adverse events evaluated by the Columbia Classification Algorithm of Suicide Assessment (C-CASA), Montgomery-Asberg Depression Rating Scale, or Beck Depression Inventory-II.
Syncope: Patients should be cautioned to avoid situations where injury could result, including driving or operating hazardous machinery, should syncope or its prodromal symptoms such as dizziness or lightheadedness occur.
Possibly prodromal symptoms such as nausea, dizziness/lightheadedness, and diaphoresis were reported more frequently among patients treated with Dapoxetine compared to placebo.
Patients with cardiovascular risk factors: Subjects with underlying cardiovascular disease were excluded from Phase 3 clinical trials. The risk of adverse cardiovascular outcomes from syncope (cardiac syncope and syncope from other causes) is increased in patients with underlying structural cardiovascular disease (e.g., documented outflow obstruction, valvular heart disease, carotid stenosis and coronary artery disease). There are insufficient data to determine whether this increased risk extends to vasovagal syncope in patients with underlying cardiovascular disease.
Use with recreational drugs: Patients should be advised not to use dapoxetine tablet in combination with recreational drugs.
Recreational drugs with serotonergic activity such as ketamine, methylene dioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD) may lead to potentially serious reactions if combined with dapoxetine tablet. These reactions include, but are not limited to, arrhythmia, hyperthermia, and serotonin syndrome. Use of dapoxetine tablet with recreational drugs with sedative properties such as narcotics and benzodiazepines may further increase somnolence and dizziness.
Ethanol: Patients should be advised not to use dapoxetine tablet in combination with alcohol.
Combining alcohol with dapoxetine tablet may increase alcohol-related neurocognitive effects and may also enhance neurocardiogenic adverse events such as syncope, thereby increasing the risk of accidental injury; therefore, patients should be advised to avoid alcohol while taking dapoxetine.
Medicinal products with vasodilatation properties: Dapoxetine tablet should be prescribed with caution in patients taking medicinal products with vasodilatation properties (such as alpha adrenergic receptor antagonists and nitrates) due to possible reduced orthostatic tolerance.
Moderate CYP3A4 inhibitors: Caution is advised in patients taking moderate CYP3A4 inhibitors and the dose is restricted to 30 mg.
Potent CYP2D6 inhibitors: Caution is advised if increasing the dose to 60 mg in patients taking potent CYP2D6 inhibitors or if increasing the dose to 60 mg in patients known to be of CYP2D6 poor metabolizer genotype, as this may increase exposure levels, which may result in a higher incidence and severity of dose dependent adverse events.
Mania: Dapoxetine tablet should not be used in patients with a history of mania/hypomania or bipolar disorder and should be discontinued in any patient who develops symptoms of these disorders.
Seizure: Due to the potential of SSRIs to lower the seizure threshold, dapoxetine tablet should be discontinued in any patient who develops seizures and avoided in patients with unstable epilepsy. Patients with controlled epilepsy should be carefully monitored.
Depression and/or psychiatric disorders: Men with underlying signs and symptoms of depression should be evaluated prior to treatment with dapoxetine tablet to rule out undiagnosed depressive disorders. Concomitant treatment of dapoxetine tablet with antidepressants, including SSRIs and SNRIs, is contraindicated. Discontinuation of treatment for ongoing depression or anxiety in order to initiate dapoxetine tablet for the treatment of PE is not recommended. Dapoxetine tablet is not indicated for psychiatric disorders and should not be used in men with these disorders, such as schizophrenia, or in those suffering with co-morbid depression, as worsening of symptoms associated with depression cannot be excluded. This could be the result of underlying psychiatric disorder or might be a result of medicinal product therapy. Physicians should encourage patients to report any distressing thoughts or feelings at any time and if signs and symptoms of depression develop during treatment, dapoxetine tablet should be discontinued.
Haemorrhage: There have been reports of bleeding abnormalities with SSRIs. Caution is advised in patients taking dapoxetine tablet, particularly in concomitant use with medicinal products known to affect platelet function (e.g., atypical antipsychotics and phenothiazines, acetylsalicylic acid, nonsteroidal anti-inflammatory drugs [NSAIDs], anti-platelet agents) or anticoagulants (e.g., warfarin), as well as in patients with a history of bleeding or coagulation disorders.
Renal impairment: Dapoxetine tablet is not recommended for use in patients with severe renal impairment and caution is advised in patients with mild or moderate renal impairment.
Withdrawal effects: Abrupt discontinuation of chronically administered SSRIs used to treat chronic depressive disorders has been reported to result in the following symptoms: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia and hypomania.
Eye disorders: The use of dapoxetine tablet has been associated with ocular effects such as mydriasis and eye pain. It should be used with caution in patients with raised intraocular pressure or those at risk of angle closure glaucoma.
Lactose intolerance: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Effects on Ability to Drive and Use Machines: Dapoxetine tablet has minor or moderate influence on the ability to drive and use machines. Dizziness, disturbance in attention, syncope, blurred vision and somnolence has been reported in subjects receiving dapoxetine tablet in clinical trials. Therefore, patients should be warned to avoid situations where injury could result, including driving or operating hazardous machinery.
Combining alcohol with dapoxetine may increase alcohol-related neurocognitive effects and may also enhance neurocardiogenic adverse events such as syncope, thereby increasing the risk of accidental injury; therefore, patients should be advised to avoid alcohol while taking Wonder.
Use in Children: Dapoxetine tablet should not be used in individuals below 18 years of age.

Dapoxetine tablet is not indicated for use by women.
Animal studies do not indicate direct or indirect harmful effects with respect to fertility, pregnancy or embryonal/foetal development.
It is not known if either dapoxetine tablet or its metabolites are excreted in human milk.

Summary of the safety profile: The following adverse drug reactions were reported during Phase 3 clinical trials most commonly and were dose related: nausea (11.0% and 22.2% in 30 mg and 60 mg prn dapoxetine groups, respectively), dizziness (5.8% and 10.9%), headache (5.6% and 8.8%), diarrhoea (3.5% and 6.9%), insomnia (2.1% and 3.9%) and fatigue (2.0% and 4.1%). The most common adverse events leading to discontinuation were nausea (2.2% of Wonder-treated subjects) and dizziness (1.2% of Wonder-treated subjects).
Very common (>1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1000 to 1/100), Rare ( ≥ 1/10000 to < 1/1000).
Psychiatric disorders: Common: Anxiety, Agitation, Restlessness, Insomnia, Abnormal dreams, Libido decreased.
Uncommon: Depression, Depressed mood, Euphoric mood, Mood altered, Nervousness, Indifference, Apathy, Confusional state, Disorientation, Thinking abnormal, Hypervigilance, Sleep disorder, Initial insomnia, Middle insomnia, Nightmare, Bruxism, Loss of libido, Anorgasmia .
Nervous system disorders: Very common: Dizziness, Headache.
Common: Somnolence, Disturbance in attention, Tremor, Paraesthesia.
Uncommon: Syncope, Syncope vasovagal, Dizziness postural, Akathisia, Dysgeusia, Hypersomnia, Lethargy, Sedation, Depressed level of consciousness.
Rare: Dizziness exertional, Sudden onset of sleep.
Eye disorders: Common: Vision blurred.
Uncommon: Mydriasis, Eye pain, Visual disturbance.
Ear and labyrinth disorders: Common: Tinnitus.
Uncommon: Vertigo.
Cardiac disorders: Uncommon: Sinus arrest, Sinus bradycardia, Tachycardia.
Vascular disorders: Common: Flushing.
Uncommon: Hypotension, Systolic hypertension, Hot flush.
Respiratory, thoracic and mediastinal disorders: Common: Sinus congestion, Yawning.
Gastrointestinal disorders: Very common: Nausea.
Common: Diarrhoea, Vomiting, Constipation, Abdominal pain, Abdominal pain upper, Dyspepsia, Flatulence, Stomach discomfort, Abdominal distension, Dry mouth.
Uncommon: Abdominal discomfort, Epigastric discomfort.
Rare: Defaecation urgency.
Skin and subcutaneous tissue disorders: Common: Hyperhidrosis.
Uncommon: Pruritis, Cold sweat.
Reproductive system and breast disorders: Common: Erectile dysfunction.
Uncommon: Ejaculation failure, Male orgasmic disorder, Paraesthesia of genital male.
General disorders and administration site conditions: Common: Fatigue, Irritability.
Uncommon: Asthenia, Feeling hot, Feeling jittery, Feeling abnormal, Feeling drunk.
Investigations: Common: Blood pressure increased.
Uncommon: Heart rate increased, Blood pressure diastolic increased, Blood pressure orthostatic increased.
Adverse drug reactions reported in the 9-month long term open label extension trial were consistent with those reported in the double blind studies and no additional adverse drug reactions were reported.
Description of selected adverse reactions: Syncope characterized as loss of consciousness, with bradycardia or sinus arrest observed in patients wearing Holter monitors, has been reported in clinical trials and is considered medicinal product-related. The majority of cases occurred during the first 3 hours after dosing, after the first dose or associated with study-related procedures in the clinical setting (such as blood draw and orthostatic maneuvers and blood pressure measurements). Prodromal symptoms often preceded the syncope.
Other special populations: Caution is advised if increasing the dose to 60 mg in patients taking potent CYP2D6 inhibitors or if increasing the dose to 60 mg in patients known to be of CYP2D6 poor metabolizer genotype.
Withdrawal effects: Abrupt discontinuation of chronically administered SSRIs used to treat chronic depressive disorders has been reported to result in the following symptoms: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia and hypomania.
Results of a safety study showed a slightly higher incidence of withdrawal symptoms of mild or moderate insomnia and dizziness in subjects switched to placebo after 62 days of daily dosing.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Pharmacodynamic Interactions: Potential for interaction with monoamine oxidase inhibitors: In patients receiving an SSRI in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued an SSRI and have been started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Animal data on the effects of combined use of an SSRI and MAOIs suggest that these medicinal products may act synergistically to elevate blood pressure and evoke behavioural excitation. Therefore, dapoxetine tablet should not be used in combination with an MAOI, or within 14 days of discontinuing treatment with an MAOI. Similarly, an MAOI should not be administered within 7 days after dapoxetine tablet has been discontinued.
Potential for interaction with thioridazine: Thioridazine administration alone produces prolongation of the QTc interval, which is associated with serious ventricular arrhythmias. Medicinal products such as dapoxetine tablet that inhibit the CYP2D6 isoenzyme appear to inhibit the metabolism of thioridazine and the resulting elevated levels of thioridazine are expected to augment the prolongation of the QTc interval. dapoxetine tablet should not be used in combination with thioridazine or within 14 days of discontinuing treatment with thioridazine. Similarly, thioridazine should not be administered within 7 days after dapoxetine tablet has been discontinued.
Medicinal/herbal products with serotonergic effects: As with other SSRIs, co-administration with serotonergic medicinal/herbal products (including MAOIs, L-tryptophan, triptans, tramadol, linezolid, SSRIs, SNRIs, lithium and St. John's Wort (Hypericum perforatum) preparations) may lead to an incidence of serotonin associated effects. Wonder tablet should not be used in combination with other SSRIs, MAOIs or other serotonergic medicinal/herbal products or within 14 days of discontinuing treatment with these medicinal/herbal products. Similarly, these medicinal/herbal products should not be administered within 7 days after dapoxetine tablet has been discontinued.
CNS active medicinal products: The use of dapoxetine tablet in combination with CNS active medicinal products (e.g., antiepileptics, antidepressants, antipsychotics, anxiolytics, and sedative hypnotics) has not been systematically evaluated in patients with premature ejaculation. Consequently, caution is advised if the concomitant administration of dapoxetine tablet and such medicinal products is required.
Pharmacokinetic Interactions: Effects of co-administered medicinal products on the pharmacokinetics of dapoxetine tablets: In vitro studies in human liver, kidney, and intestinal microsomes indicate dapoxetine tablet is metabolized primarily by CYP2D6, CYP3A4 and flavin monooxygenase 1 (FMO1). Therefore, inhibitors of these enzymes may reduce Dapoxetine clearance.
CYP3A4 inhibitors: Potent CYP3A4 inhibitors: Administration of ketoconazole (200 mg twice daily for 7 days) increased the C_max and AUC_inf of dapoxetine tablet (60 mg single dose) by 35% and 99%, respectively. Considering the contribution of both unbound Dapoxetine and desmethyldapoxetine, the C_max of the active fraction may be increased by approximately 25% and the AUC of the active fraction may be doubled if taken with potent CYP3A4 inhibitors.
The increases in the C_max and AUC of the active fraction may be markedly increased in a part of the population which lack a functional CYP2D6 enzyme, i.e., CYP2D6 poor metabolizers, or in combination with potent inhibitors of CYP2D6.
Therefore, concomitant use of dapoxetine tablet and potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir and atazanavir, is contraindicated.
Moderate CYP3A4 inhibitors: Concomitant treatment with moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem) may also give rise to significantly increased exposure of Dapoxetine and desmethyldapoxetine, especially in CYP2D6 poor metabolizers. The maximum dose of Wonder tablet should be 30 mg if it is combined with any of these drugs.
These two measures apply to all patients unless the patient has been verified to be a CYP2D6 extensive metabolizer by geno- or phenotyping. In patients verified to be CYP2D6 extensive metabolizers, a maximum dose of 30 mg is advised if dapoxetine tablet is combined with a potent CYP3A4 inhibitor and caution is advised if dapoxetine tablet in 60 mg doses is taken concomitantly with a moderate CYP3A4 inhibitor.
Potent CYP2D6 inhibitors: The C_max and AUC_inf of dapoxetine tablet (60 mg single dose) increased by 50% and 88%, respectively, in the presence of fluoxetine (60 mg/day for 7 days). Considering the contribution of both unbound Dapoxetine and desmethyldapoxetine, the C_max of the active fraction may be increased by approximately 50% and the AUC of the active fraction may be doubled if taken with potent CYP2D6 inhibitors. These increases in the C_max and AUC of the active fraction are similar to those expected for CYP2D6 poor metabolizers and may result in a higher incidence and severity of dose dependent adverse events.
PDE5 inhibitors: Wonder tablet should not be used in patients using PDE5 inhibitors due to possible reduced orthostatic tolerance. The pharmacokinetics of Dapoxetine (60 mg) in combination with tadalafil (20 mg) and sildenafil (100 mg) were evaluated in a single dose crossover study. Tadalafil did not affect the pharmacokinetics of Dapoxetine. Sildenafil caused slight changes in Dapoxetine pharmacokinetics (22% increase in AUC_inf and 4% increase in C_max), which are not expected to be clinically significant.
Concomitant use of Dapoxetine with PDE5 inhibitors may result in orthostatic hypotension. The efficacy and safety of Wonder tablet in patients with both premature ejaculation and erectile dysfunction concomitantly treated with Wonder and PDE5 inhibitors have not been established.
Effects of dapoxetine tablet on the pharmacokinetics of co-administered medicinal products Tamsulosin: Concomitant administration of single or multiple doses of 30 mg or 60 mg dapoxetine tablet to patients receiving daily doses of tamsulosin did not result in changes in the pharmacokinetics of tamsulosin. The addition of dapoxetine tablet to tamsulosin did not result in a change in the orthostatic profile and there were no differences in orthostatic effects between tamsulosin combined with either 30 or 60 mg dapoxetine tablet and tamsulosin alone; however, dapoxetine tablet should be prescribed with caution in patients who use alpha adrenergic receptor antagonists due to possible reduced orthostatic tolerance.
Medicinal products metabolized by CYP2D6: Multiple doses of dapoxetine tablet (60 mg/day for 6 days) followed by a single 50 mg dose of desipramine increased the mean C_max and AUC_inf of desipramine by approximately 11% and 19%, respectively, compared to desipramine administered alone. Dapoxetine metabolized by CYP2D6. The clinical relevance is likely to be small.
Medicinal products metabolized by CYP3A4: Multiple dosing of dapoxetine tablet (60 mg/day for 6 days) decreased the AUC_inf of midazolam (8 mg single dose) by approximately 20% (range -60 to +18%). The clinical relevance of the effect on midazolam is likely to be small in most patients. The increase in CYP3A activity may be of clinical relevance in some individuals concomitantly treated with a medicinal product mainly metabolized by CYP3A and with a narrow therapeutic window.
Medicinal products metabolized by CYP2C19: Multiple dosing of dapoxetine tablet (60 mg/day for 6 days) did not inhibit the metabolism of a single 40 mg dose of omeprazole. Dapoxetine tablet is unlikely to affect the pharmacokinetics of other CYP2C19 substrates.
Medicinal products metabolized by CYP2C9: Multiple dosing of dapoxetine tablet (60 mg/day for 6 days) did not affect the pharmacokinetics or pharmacodynamics of a single 5 mg dose of glyburide. Dapoxetine tablet is unlikely to affect the pharmacokinetics of other CYP2C9 substrates.
Warfarin and medicinal products that are known to affect coagulation and/or platelet function: There are no data evaluating the effect of chronic use of warfarin with dapoxetine tablet; therefore, caution is advised when dapoxetine tablet is used in patients taking warfarin chronically. In a pharmacokinetic study, dapoxetine tablet (60 mg/day for 6 days) did not affect the pharmacokinetics or pharmacodynamics (PT or INR) of warfarin following a single 25 mg dose.
There have been reports of bleeding abnormalities with SSRIs.
Ethanol: Co-administration of a single dose of ethanol, 0.5 g/kg (approximately 2 drinks), did not affect the pharmacokinetics of dapoxetine tablet (60 mg single dose); however, dapoxetine tablet in combination with ethanol increased somnolence and significantly decreased self-rated alertness. Pharmacodynamic measures of cognitive impairment (Digit Vigilance Speed, Digit Symbol Substitution Test) also showed an additive effect when Wonder tablet was coadministered with ethanol. Concomitant use of alcohol and dapoxetine tablet increases the chance or severity of adverse reactions such as dizziness, drowsiness, slow reflexes, or altered judgment. Combining alcohol with dapoxetine tablet may increase these alcohol-related effects and may also enhance neurocardiogenic adverse events such as syncope, thereby increasing the risk of accidental injury; therefore, patients should be advised to avoid alcohol while taking dapoxetine tablet.

Store below 30°C.
Shelf Life: 36 months.

Drugs for Erectile Dysfunction & Ejaculatory Disorders

G04BX14 - dapoxetine ; Belongs to the class of other urologicals.

POM

FC tab (grey coloured, round, biconvex, plain on both sides) 30 mg x 4's. 60 mg x 4's.